John H. Glick, MD

home / authors / john-h-glick-md

Articles

Tamoxifen's Impact on the Management of Breast Cancer: The Oncologist's Perspective

John H. Glick, MD;John Wallmark, MD

February 1st 1997

Breast cancer treatment has evolved greatly within the last 25 years. Tamoxifen was first introduced for the

Benefits of Tamoxifen Outweigh Endometrial Cancer Risk

V. Craig Jordan, OBE, PhD, DSc;Richard R. Barakat, MD;John H. Glick, MD;Anthony Howell, MD;Robert W. Morgan, MD;Joseph Ragaz, MD;Bonnie S. Reichman, MD;Nicholas J. Robert, MD;James A. Swenberg, DVM, PhD

November 1st 1996

An expert panel of nine international cancer researchers and practicing oncologists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer. The first article in this series, based on the symposium presentations, focused on the optimal duration of tamoxifen use (October 1996). This month, the panel explores the noncancer benefits of tamoxifen, as well as the potential risk of endometrial cancer. The symposium was sponsored by Zeneca Pharmaceuticals.